Maureane Hoffman

Conference Blood · November 5, 2024 Introduction: Antithrombin (AT) is the dominant thrombin inhibitor under normal conditions. Hemophilia is a defect in thrombin generation (TG). One novel therapeutic approach for rebalanc ... Full text Cite

THROMBOSIS AND THE NOVEL HAEMOPHILIA THERAPIES

Conference HAEMOPHILIA · February 2022 Link to item Cite

Emizicumab Promotes Factor Xa Generation on Activated Endothelium in a Blood Cell-Independent Manner

Conference Blood · November 5, 2021 AbstractIntroductionHemophilia A (HA) is an inherited bleeding disorder caused by the deficiency of coagulation factor VIII (FVIII) resulting in severe hemorrhage if untreate ... Full text Cite

In Hemophilia Α Plasma Treated with Emicizumab, Factor IXa in Activated Prothrombin Complex Concentrates Is the Dominant Contributor to Enhanced Thrombin Generation

Conference Blood · November 5, 2020 Background. Recently a novel bifunctional antibody (emicizumab) that binds both factor IXa and factor X has been used to treat hemophilia A. Emicizumab has proven remarkably effective as a prophylactic treatment for hemophilia A; however there are ... Full text Cite

In Hemophilia Α Plasma Treated with Emicizumab, Factor IX Activation By Factor VIIa Drives Thrombin Generation

Conference Blood · November 5, 2020 Background.Recently a novel bifunctional antibody (emicizumab) that binds both factor IXa (FIXa) and factor X (FX) has been used to treat hemophilia A. Emicizumab has proven remarkably effective as a prophylactic treatment for hemophilia A; however ... Full text Cite

Aortic Ring Angiogenesis is Maintained Despite Minimal Expression of Tissue Factor

Conference ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY · May 2020 Link to item Cite

Increased Aortic Ring Angiogenesis in Von Willebrand Factor Knockout Mice is Mediated Through a VEGF Receptor-2-independent Mechanism

Conference ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY · May 2020 Link to item Cite

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

Conference Blood · November 13, 2019 While prophylactic treatment with emicizumab has shown remarkable efficacy in patients with hemophilia A, the treatment options for traumatic, perioperative, and breakthrough bleeding in hemophilia A or B patients with inhibitors remain extremely l ... Full text Cite

In the presence of emicizumab, factor VIIa activation of factor IX contributes to factor Xa generation

Conference HAEMOPHILIA · February 1, 2019 Link to item Cite

Biochemical Characteristics of Emicizumab Activity with Factors IXa, X, and VIIa

Conference Blood · November 29, 2018 AbstractIntroduction. Emicizumab (Hemlibra) is a bivalent antibody that binds to factor IXa and factor X; this binding can promote factor IXa activation of factor X. In patients on prophylaxis with emicizuma ... Full text Cite

Nitric Oxide Mediates Downregulation of Tissue Factor Expression in Primary Human Pericytes through a p38 MAPK Signaling Pathway

Conference Blood · November 29, 2018 AbstractTissue factor (TF) is a high-affinity receptor for FVII/FVIIa that serves as a key initiator of hemostasis and is thought to also play a functional role in angiogenesis. Elevated TF expression has be ... Full text Cite

Abstract 288: Nitric Oxide Mediates Active Downregulation of Tissue Factor Expression in Human Pericytes

Conference Arteriosclerosis, Thrombosis, and Vascular Biology · May 2018 Tissue Factor (TF) is a transmembrane protein that not only expresses pro-coagulant enzymatic activity, but also mediates signal transduction by several second messenger pathways. It plays an obvious role in hemostasis and thrombosis, ... Full text Cite

Platelet-Like-Particles Mediate Matrix Properties to Promote Cell Migration in a Hemophilia Wound Healing Model

Conference TISSUE ENGINEERING PART A · December 1, 2017 Link to item Cite

Inhibition of von Willebrand Factor Activity Does Not Delay Cutaneous Wound Healing

Conference ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY · May 1, 2017 Link to item Cite

Specific Protein Kinase C Isoforms Are Critical Mediators of Physiologic Downregulation of Perivascular Tissue Factor

Conference ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY · May 1, 2017 Link to item Cite

THE COAGULOPATHY ASSOCIATED WITH SYSTEMIC ACIDOSIS IS NOT REFLECTED IN ROUTINE LABORATORY TESTING USING A MODERN LINE OF REAGENTS

Conference AMERICAN JOURNAL OF HEMATOLOGY · September 1, 2016 Link to item Cite

A Controlled Trial of Plateletpheresis during Cardiac Surgery

Conference TRANSFUSION · September 1, 2016 Link to item Cite

The effects of a long-acting factor IX product (N9-GP) on wound healing

Conference HAEMOPHILIA · July 1, 2016 Link to item Cite

Phorbol 12-myristate 13-acetate Downregulates Tissue Factor Gene Expression in Human Pericytes

Conference ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY · May 2016 Link to item Cite

Comprehensive Safety Assessment of Factor VIIA-CTP, A Novel Long Acting FVIIA, Supporting the on-Going Clinical Program

Conference HAEMOPHILIA · February 2016 Link to item Cite

FVIIA-CTP, a Long Acting FVIIA, Proposing a Novel Treatment by Less Frequent Subcutaneous or Intravenous Injections Compared to rFVIIA: Pharmacological Feasibility in Small and Large Hemophilic Animal Models

Conference HAEMOPHILIA · February 2016 Link to item Cite

Ex-Vivo and In-Vitro Evaluation of Factor VIIA-CTP'S Mechanism of Action, A Novel Long-Acting FVIIA Coagulation Factor

Conference HAEMOPHILIA · February 2016 Link to item Cite

Downregulation of Tissue Factor in Pericytes By a Protein Kinase C-Dependent Mechanism

Conference Blood · December 3, 2015 AbstractTissue factor (TF) is a transmembrane protein in the type II cytokine receptor family that serves as a cofactor for factor VIIa activity, and is essential for normal initiation of hemostasis. Its exp ... Full text Cite